The present study showed that ten hub genes (IL6, EGFR, STAT3, MMP9, CD44, FN1, CD4, TGFB1, CXCL8, CCL2) with higher node degree in PPI networks have been predicted to be survival biomarkers for GBM patients and some have been experimentally validated. The gene discussed is CCL2; the disease is glioblastoma.